Revolution Medicines reports updated pancreatic cancer data for daraxonrasib at ENA 2026
Revolution Medicines presented updated Phase 1/2 data on daraxonrasib with chemotherapy in first-line metastatic pancreatic cancer at ENA 2026 in Barcelona.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Revolution Medicines published updated results from its Phase 1/2 RMC-GI-102 study, according to a press release distributed via GlobeNewswire. The data cover RASONQUE (daraxonrasib) given with gemcitabine and nab-paclitaxel as a first-line option for metastatic pancreatic adenocarcinoma.
As of September 28, 2026, 61 patients had been included, with a median follow-up of 18.3 months. The company reported an objective response rate of 60.7%, with full responses in 8.2% of patients, and median progression-free survival of 12.8 months. Twelve-month overall survival reached 76.6%. The company said the safety profile matched what was previously seen for both drugs. The presentation is scheduled as a late-breaking oral session at the ENA Symposium in Barcelona on November 20, 2026.
why it matters
The FDA granted Breakthrough Therapy Designation for this combination, and the drug is already approved in the US and EU for patients who have received at least one prior systemic therapy. The Phase 3 RASolute 303 trial in untreated patients is the next major test, so investors are likely to focus on its readout rather than on this open-label data alone.
market impact
Revolution Medicines shares: encouraging trial data supports investor interest in the company
- Revolution Medicines shares pressure up — encouraging trial data and breakthrough designation support interest in the stock
tags
instruments
sources
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗